1-20 of 4014 Search Results for

treat lymphoma leukemia myeloma

Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Images
Up-regulation of proteasome pathway and the growth inhibitory effect of pro...

Up-regulation of proteasome pathway and the growth inhibitory effect of pro...

in Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia > Blood
Published: 2010
Figure 5 Up-regulation of proteasome pathway and the growth inhibitory effect of proteasome inhibitors on T-ALL cells . (A) GSEA histograms for human T-ALL cells (cell lines or primary clinical samples) representing the “proteasome pathway.” The NES and the nominal P value are indicated. GSI-tr... More about this image found in Up-regulation of proteasome pathway and the growth inhibitory effect of pro...
Images
15d-PGJ 2 inhibits constitutive NF- κ B binding activity and induces apop...

15d-PGJ 2 inhibits constitutive NF- κ B binding activity and induces apop...

in 15-Deoxy-Δ 12,14 -prostaglandin J 2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-κB activity and down-regulation of antiapoptotic proteins > Blood
Published: 2005
Figure 6. 15d-PGJ 2 inhibits constitutive NF- κ B binding activity and induces apoptosis in different types of B-cell malignancies. (A) Burkitt lymphoma HS-Sultan and BL-41 cells, multiple myeloma U266 and RPMI-8226 cells, and acute leukemia K562 cells (0.5 × 10 6 cell/mL) were treated with ... More about this image found in 15d-PGJ 2 inhibits constitutive NF- κ B binding activity and induces apop...
Images
A 73-year-old man with a 2-year history of bilateral lung transplantation p...

A 73-year-old man with a 2-year history of bilateral lung transplantation p...

in Plasmablastic myeloma/leukemia variant of monomorphic posttransplant lymphoproliferative disorder > Blood
Published: 2021
A 73-year-old man with a 2-year history of bilateral lung transplantation presented with progressive fatigue, nausea, and night sweats over the past 2 months. Laboratory tests showed abnormal serum components: creatinine, 460.0 µmol/L; lactate dehydrogenase, 3073 U/L; immunoglobulin A (IgA) lambda p... More about this image found in A 73-year-old man with a 2-year history of bilateral lung transplantation p...
Images
ActD treatment induces cell death in human TP53 wt B-cell <span class="search-highlight">lymphomas</span>. (A...

ActD treatment induces cell death in human TP53 wt B-cell lymphomas. (A...

in Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death > Blood
Published: 2021
Figure 5. ActD treatment induces cell death in human TP53 wt B-cell lymphomas. (A) ActD IC 50 values of a data set with 740 tumor cell lines from the Genomics of Drug Sensitivity in Cancer (GDSC) database ranked by sensitivity to ActD (left) and box plot showing IC 50 values of hematologic ... More about this image found in ActD treatment induces cell death in human TP53 wt B-cell lymphomas. (A...
Journal Articles

Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia

Daniela Barraco, MD, Terra L. Lasho, PhD, Christy Finke, BS, Aref Al-Kali, MD, Michelle Elliott, MD, Mark R. Litzow, MD, Naseema Gangat, MBBS, Curtis A. Hanson, MD, Ayalew Tefferi, MD, Mrinal M Patnaik, MBBS
Journal: Blood
Blood (2016) 128 (22): 1989.
https://doi.org/10.1182/blood.V128.22.1989.1989
Published: 2016
... malignancies included: MM (n=1, 8%), diffuse large B-cell lymphoma (n=1, 8%), Waldenström's macroglobulinemia (n=1, 8%), CLL (n=2, 15%) and acute lymphoblastic leukemia (n=1, 8%). Four (31%) patients needed chemotherapy, with outcomes including: complete remission in one case (multiple myeloma), progression...
Journal Articles

Enrollment of Older Adults in Clinical Trials Evaluating Patients with Hematologic Malignancies - the Food and Drug Administration (FDA) Experience

Bindu Kanapuru, MD, Harpreet Singh, MD, Adrian Myers, Julia A. Beaver, MD, Virginia Elaine Kwitkowski, MS,NP, Ann T. Farrell, MD, Richard Pazdur, MD
Journal: Blood
Blood (2017) 130 (Suppl_1): 861.
https://doi.org/10.1182/blood.V130.Suppl_1.861.861
Published: 2017
... distributions of <65, 65-74 and ≥ 75 years. The rates of enrollment for patients with chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and lymphomas (Hodgkin's and non-Hodgkin's lymphoma excluding CLL) were compared with the age distribution of incidence cases by site...
Journal Articles

Risk of Developing Second Cancers in Plasmacytoma in United States

Vivek Kumar, MD, Neha Chaudhary, MD, Vishangi Dave, MD, Abhinav B Chandra, MD MSc, FACP
Journal: Blood
Blood (2016) 128 (22): 4443.
https://doi.org/10.1182/blood.V128.22.4443.4443
Published: 2016
...). The risk was higher for developing multiple myeloma (SIR 30.8 25-38 AER 67/10,000), leukemia (SIR 3.4, 95% CI; 2-5.2 AER 10/10,000) and non-Hodgkin's lymphoma (NHL) (SIR 3.2, 95 % CI 2.1-4.7 AER 13.4/10,000) in "two-month" survivors of plasmacytoma as compared to general population. The risk of developing...
Journal Articles

AO-176, a Differentiated Clinical-Stage Anti-CD47 Antibody, Demonstrates Potent Anti-Tumor Activity across Multiple Preclinical Models of B Cell Neoplasms

William Casey Wilson, John O Richards, Gabriela Andrejeva, Benjamin J Capoccia, Robyn J Puro, Mike J Donio, Ronald R Hiebsch, Arun K Kashyap, Daniel S Pereira
Journal: Blood
Blood (2021) 138 (Supplement 1): 2277.
https://doi.org/10.1182/blood-2021-152896
Published: 2021
... to red blood cells, non-ADCC direct tumor killing and elicits immunogenic cell death and DAMP induction, all in addition to single-agent phagocytosis. In vivo, AO-176 has exhibited broad anti-tumor activity in preclinical xenograft models of multiple myeloma (MM), acute myeloid leukemia, T cell acute...
Journal Articles

Pharmacological Perturbation of the Immunoproteasome in Hematologic Neoplasias: Therapeutic Implications

Sondra L. Downey-Kopyscinski, PhD, Ricardo De Matos Simoes, PhD, Megan Bariteau, BSc, Minasri L. Borah, Sam Bender, Janaka Foneska, Jennifer Roth, Richard Groen, Gina Walter, Manja Friese-Hamim, Samantha M. Goodstal, Michael Sanderson, Constantine S. Mitsiades, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1291.
https://doi.org/10.1182/blood-2019-130356
Published: 2019
... "DNA-barcoded" cell lines (PRISM system) from hematologic malignancies, including multiple myeloma (MM), leukemias and lymphomas, which were treated for 48hr with M3258. MM cell lines (9/16) were strongly represented among the sensitive lines which displayed <50% relative cell viability (compared...
Journal Articles

Four Cases of Lenalidomide-Associated Immune Thrombocytopenia

Alessandra Pompa, MD, Francesca Guidotti, MD, Anna Ines Gregorini, MD, Maria Cecilia Goldaniga, MD, Francesca Gaia Rossi, MD, Luca Baldini, MD Prof, Agostino Cortelezzi, MD
Journal: Blood
Blood (2016) 128 (22): 4927.
https://doi.org/10.1182/blood.V128.22.4927.4927
Published: 2016
... in non‐Hodgkin lymphomas (NHL) and especially chronic lymphocytic leukemia (CLL); until now only few cases have been described in patients affected by multiple myeloma (MM) and other plasma cell disorders. The introduction of new drugs, in particular immunomodulatory drugs (IMiDs), could increase...
Journal Articles

Phase I Studies in Hematologic Malignancy: 20-Year Experience from Cancer Therapy Evaluation Program (CTEP) at National Cancer Institute/National Institutes of Health

Dai Chihara, MDPhD, Erich P. Huang, PhD, Shanda R. Finnigan, MPH, RN, Lisa M. Cordes, PharmD, Nebojsa Skorupan, MD, Yoko Korenaga Fukuda, MD, Larry V. Rubinstein, PhD, Naoko Takebe, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18.
https://doi.org/10.1182/blood-2020-140159
Published: 2020
... was administered were assessed through likelihood ratio tests of a generalized linear mixed model. Results Overall, 3,308 patients were treated in 161 trials. Median age of the patients was 61 (range: 0-96) and 61% were male. Acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) was the most common enrolled...
Journal Articles

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

John Richards, PhD, Myriam N Bouchlaka, BS,PhD, Robyn J Puro, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, W. Casey Wilson, PhD, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1844.
https://doi.org/10.1182/blood-2019-126298
Published: 2019
... hematologic cancers in vitro and in vivo. As a single agent, AO-176 not only promotes phagocytosis (15-45%, EC 50 = 0.33-4.1 µg/ml) of hematologic tumor cell lines (acute myeloid leukemia, non-Hodgkin's lymphoma, multiple myeloma, and T cell leukemia) but also directly targets and kills tumor cells (18-46...
Journal Articles

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Lori S. Muffly, MDMS, Kevin Sheehan, PhD, Randall Armstrong, Keri Tate, PhD, Cynthia Tudisco, Andrew R. Rezvani, MD, David Miklos, MD PhD, Sally Arai, MD, Judith Shizuru, MD PhD, Laura Johnston, Everett Meyer, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Robert S Negrin, MD, Sam Strober, Robert Lowsky, MD
Journal: Blood
Blood (2016) 128 (22): 4615.
https://doi.org/10.1182/blood.V128.22.4615.4615
Published: 2016
... + memory T cell infusion at three dose levels. Median age was 59 years (range, 29 to 70 years). Diagnoses included acute myeloid leukemia (n= 8), non-Hodgkin lymphoma (n= 3), chronic lymphocytic leukemia (n= 1), chronic myeloid leukemia (n=1), multiple myeloma (n=1), and acute lymphoblastic leukemia (n=1...
Journal Articles

Exposure-Response of the Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in the Treatment of Hematologic Malignancies

Feng Jin, PhD, Ming Yin, PhD, Vinay Mandava, Helena Edlund, PhD, Marilee Andrew, PhD, Priti Patel, MD, Eric Masson, PharmD, Nidal Al-Huniti, PhD, Xiaolin Wang, ScD, J. Greg Slatter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1268.
https://doi.org/10.1182/blood.V130.Suppl_1.1268.1268
Published: 2017
.../refractory (R/R) mantle cell lymphoma (MCL). The relationship between acalabrutinib plasma exposure and safety was evaluated in patients with B-cell malignancies that included R/R MCL, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, multiple myeloma and Waldenström...
Journal Articles

SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies

Peter U. Park, Véronique Blanc, Jutta Deckert, Pascale Lejeune, Laura M. Bartle, Anna Skaletskaya, Michele F. Mayo, Chonghui Zhang, Marie-Cécile Wetzel, Daniel J. Tavares, Robert J. Lutz, Thomas Chittenden, Marie-Christine Bissery, John M. Lambert, Victor S. Goldmacher
Journal: Blood
Blood (2008) 112 (11): 2756.
https://doi.org/10.1182/blood.V112.11.2756.2756
Published: 2008
... for antibody therapeutics for the treatment of various hematological malignancies, including multiple myeloma as well as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. CD38 is a type II transmembrane glycoprotein...
Journal Articles

Outcome of Relapse after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - The Effect of the Underlying Disease on Survival Following Relapse.

Seema Singhal, Olga Frankfurt, Andrew Evens, Leo Gordon, Martin Tallman, Stephanie Williams, Jane Winter, David Grinblatt, Lynne Kaminer, Jayesh Mehta
Journal: Blood
Blood (2007) 110 (11): 5020.
https://doi.org/10.1182/blood.V110.11.5020.5020
Published: 2007
..., this observation continues to remain valid in a series of 91 uniformly-treated patients with hematologic malignancies (19–71 years; median 53; 22% >60 years). 29 patients had acute leukemia, 38 had lymphoma (Hodgkin/NHL) or CLL, and 24 had myeloma. Two-thirds of the patients had refractory disease. Performance...
Journal Articles

Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies

Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Tayyab Rehan, MBBS, Muhaddis Ejaz Ahmad, MD, Syeda Sabeeka Batool, MBBS, MD, Muhammad Abdullah Yousaf, MBBS, MD, Maaz Ahmed Yusufi, MD, Saif Ur Rehman, MBBS, MD, Sravanthi Kotapati, MBBS, Maimoona Khan, MBBS, Asma Waheed, MBBS, Zainab Ijaz, Awais Ijaz, MD, Faiz Anwer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4442.
https://doi.org/10.1182/blood-2019-127452
Published: 2019
... trial (NCT01029366 / B lymphoma, leukemia / CD19 target / n=20) showed 3 cases (15%) of pneumonia, 1 case each of C Diff, Pseudomonas and salmonella (5%) infections. A Phase 2 trial (NCT02030834, B NHL, CD19 target, n=63) treated patients showed 34% patients experienced infection which included sepsis...
Journal Articles

Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study

Yukinari Sanada, MD, Kimikazu Yakushijin, MD, Tetsuhiko Nomura, MD, Katsuya Yamamoto, MD, Keiji Kurata, MD, Kei Takenaka, MD, Seiji Kakiuchi, MD, Yoshiharu Miyata, MD, Yoshinori Imamura, MD, Meiko Nishimura, MD, Yohei Funakoshi, MD, Yuriko Iwamoto, MD, Naoko Chayahara, MD, Masanori Toyoda, MD, Yosuke Minami, MD, Naomi Kiyota, MD, Toru Mukohara, MD, Shinichiro Kawamoto, MD, Yohei Shimono, MD, Mitsuhiro Ito, MD, Hiroshi Matsuoka, MD, Hironobu Minami, MD
Journal: Blood
Blood (2014) 124 (21): 4131.
https://doi.org/10.1182/blood.V124.21.4131.4131
Published: 2014
.... Results: A total of 109 patients (median age 61 years [range 21–89 years]) were enrolled; 55 females and 54 males, 36 hematological malignancies (multiple myeloma [n=15], malignant lymphoma [n=10], chronic myeloid leukemia [n=10], and acute lymphoblastic leukemia [n=1]), 70 solid tumors (breast [n=14...
Journal Articles

Exquisite Sensitivity of Plasma Cell Malignancies to a Novel Nucleoside Analog Is Mediated By Overexpressed Adenosine Kinase

Utthara Nayar, Jouliana Sadek, Jonathan B Reichel, David Bunn, Denise Hernandez-Hopkins, Peter Barelli, Michelle Sahai, Jennifer Totonchy, Sei Shizuko, Robert Shoemaker, David Warren, Olivier Elemento, Kenneth Kaye, Ethel Cesarman
Journal: Blood
Blood (2015) 126 (23): 1812.
https://doi.org/10.1182/blood.V126.23.1812.1812
Published: 2015
... be sensitive to 6-ETI, which we documented for primary specimens of PEL, multiple myeloma and other lymphoid malignancies with plasmacytic features, namely plasmablastic lymphoma. A number of nucleoside analogues have been reported to be effective in treating leukemias and B and T cell lymphomas. We performed...
Journal Articles

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

Merav Bar, MD, Barry Storer, PhD, Benedetto Bruno, MD, Parameswaran Hari, MBBS, MD, MRCP, Thomas Chauncey, MD, PhD, Yoshihiro Inamoto, MD, PhD, Paul J. Martin, MD, Rainer Storb, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Mary E.D. Flowers, MD
Journal: Blood
Blood (2012) 120 (21): 354.
https://doi.org/10.1182/blood.V120.21.354.354
Published: 2012
... was given for treatment of chronic myeloid leukemia (n=56), acute myeloid leukemia (n=71), myelodysplastic syndrome (n=25), acute lymphoblastic leukemia (n=21), multiple myeloma (n=23), lymphoma (n=21) and chronic lymphocytic leukemia/lymphoma (n=11). Patients received transplants from HLA-matched related...